CN114127063A - 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途 - Google Patents

嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途 Download PDF

Info

Publication number
CN114127063A
CN114127063A CN202080029927.1A CN202080029927A CN114127063A CN 114127063 A CN114127063 A CN 114127063A CN 202080029927 A CN202080029927 A CN 202080029927A CN 114127063 A CN114127063 A CN 114127063A
Authority
CN
China
Prior art keywords
compound
substituted
unsubstituted
methyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080029927.1A
Other languages
English (en)
Other versions
CN114127063B (zh
Inventor
王猛
朱卫星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitas Biosciences Shanghai Co Ltd
Original Assignee
Epitas Biosciences Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitas Biosciences Shanghai Co Ltd filed Critical Epitas Biosciences Shanghai Co Ltd
Publication of CN114127063A publication Critical patent/CN114127063A/zh
Application granted granted Critical
Publication of CN114127063B publication Critical patent/CN114127063B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明涉及一种嘧啶并五元杂环类化合物及其作为突变型IDH2抑制剂的用途，具体地，本发明公开了一种可作为突变型IDH2抑制剂的嘧啶并五元杂环类化合物、或其立体异构体或互变异构体、或药学上可接受的盐、水合物或溶剂化物。本发明还涉及包含上述化合物的药物组合物及其用于制备预防和/或治疗突变型IDH2介导的疾病的药物的用途。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080029927.1A 2019-04-22 2020-03-30 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途 Active CN114127063B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019103246792 2019-04-22
CN201910324679.2A CN111825674A (zh) 2019-04-22 2019-04-22 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
PCT/CN2020/082016 WO2020215998A1 (zh) 2019-04-22 2020-03-30 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途

Publications (2)

Publication Number Publication Date
CN114127063A true CN114127063A (zh) 2022-03-01
CN114127063B CN114127063B (zh) 2023-12-01

Family

ID=72912323

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910324679.2A Pending CN111825674A (zh) 2019-04-22 2019-04-22 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN202080029927.1A Active CN114127063B (zh) 2019-04-22 2020-03-30 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910324679.2A Pending CN111825674A (zh) 2019-04-22 2019-04-22 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途

Country Status (5)

Country Link
US (1) US20220204509A1 (zh)
EP (1) EP3967691A4 (zh)
JP (1) JP2022530371A (zh)
CN (2) CN111825674A (zh)
WO (1) WO2020215998A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107556366A (zh) * 2016-06-30 2018-01-09 上海海和药物研究开发有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
WO2024035771A2 (en) * 2022-08-09 2024-02-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Ulk3 inhibitors and uses thereof
CN116478172B (zh) * 2023-06-20 2023-09-05 英矽智能科技(上海)有限公司 吡咯并[3,2-d]嘧啶类化合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035118A1 (en) * 2015-08-25 2017-03-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2017069960A1 (en) * 2015-10-19 2017-04-27 The Scripps Research Institute Inhibitors of sulfur metabolism with potent bactericidal activity against mdr and xdr m. tuberculosis
WO2017140758A1 (en) * 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
WO2019024908A1 (zh) * 2017-08-04 2019-02-07 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897307B2 (en) * 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
AU2003265636A1 (en) * 2002-09-06 2004-03-29 Smithkline Beecham Corporation Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds
CA2577745C (en) * 2004-09-30 2012-11-27 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
PE20151495A1 (es) * 2012-11-15 2015-10-23 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035118A1 (en) * 2015-08-25 2017-03-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN108349976A (zh) * 2015-08-25 2018-07-31 百时美施贵宝公司 TGFβ受体拮抗剂
WO2017069960A1 (en) * 2015-10-19 2017-04-27 The Scripps Research Institute Inhibitors of sulfur metabolism with potent bactericidal activity against mdr and xdr m. tuberculosis
WO2017140758A1 (en) * 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
WO2019024908A1 (zh) * 2017-08-04 2019-02-07 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL LIBRARY等数据库: "《STN检索结果》", 11 December 2011 *
NIELSEN, FLEMMING E.等: "Phosphorus pentoxide in organic synthesis. XV. A new synthesis of adenines from 4-acylamino-1H-imidazole-5-carbonitriles", 《CHEMICA SCRIPTA》 *
NIELSEN, FLEMMING E.等: "Phosphorus pentoxide in organic synthesis. XV. A new synthesis of adenines from 4-acylamino-1H-imidazole-5-carbonitriles", 《CHEMICA SCRIPTA》, vol. 24, no. 4, 31 December 1984 (1984-12-31), pages 208 - 223, XP008061054 *
李宙阳等: "刃天青法检测K562细胞对几种抗肿瘤药物的敏感性", 《山地农业生物学报》 *
李宙阳等: "刃天青法检测K562细胞对几种抗肿瘤药物的敏感性", 《山地农业生物学报》, vol. 33, no. 02, 31 December 2014 (2014-12-31) *

Also Published As

Publication number Publication date
EP3967691A1 (en) 2022-03-16
US20220204509A1 (en) 2022-06-30
EP3967691A4 (en) 2022-12-28
JP2022530371A (ja) 2022-06-29
WO2020215998A1 (zh) 2020-10-29
CN114127063B (zh) 2023-12-01
CN111825674A (zh) 2020-10-27

Similar Documents

Publication Publication Date Title
CN107108583B (zh) 可用作激酶抑制剂的吲哚甲酰胺化合物
CN104837829B (zh) 抑制剂化合物
CN112142735B (zh) 一类稠和氰基吡啶类化合物、制备方法和用途
EP2485731B1 (en) Heterocyclic compounds useful as pdk1 inhibitors
CN113544128A (zh) Kras-g12c抑制剂
CN115836072A (zh) Kras g12c蛋白的抑制剂和其用途
JP2023511337A (ja) ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用
CN114127063B (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN112055709A (zh) 吡嗪化合物和其用途
TW201734021A (zh) 布魯頓氏（ｂｒｕｔｏｎ）酪胺酸激酶抑制劑及其使用方法
CN114341127A (zh) 作为hpk1抑制剂的氨基吡嗪化合物及其用途
EP3694330B1 (en) Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US20160297815A1 (en) 7-azaindole or 4,7-diazaindole derivatives as ikk epsilon and tbk1 inhibitor and pharmaceutical composition comprising same
CN113061132A (zh) 一类稠环内酰胺类化合物、制备方法和用途
WO2021115457A9 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN112457326B (zh) 一类芳香杂环并内酰胺类化合物、制备方法和用途
CN110950876A (zh) 一类呋喃并内酰胺类化合物、制备方法和用途
TW201240971A (en) Fused heterocyclic compounds
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
CN114685487A (zh) 一类嘧啶并杂环类化合物、制备方法和用途
TW202115061A (zh) 一類具有brd4抑制活性的化合物、其製備方法及用途
CN115867346A (zh) 激酶抑制剂
CN112300154A (zh) 一类含氮杂环化合物、其制备方法和用途
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
CN111747954B (zh) 吡嗪化合物和其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant